As the year comes to a close, we revisit some of this year’s top content on kidney cancer.There’s been an abundance of news surrounding kidney cancer advances over the last year. In honor of these breakthroughs, Urology Times® is highlighting our top content on renal cancer from 2023.Pembrolizumab plus lenvatinib shows promise in nccRCCData from […]
